Grim excavation begins at site believed to contain remains of around 800 babies

Irish officials have begun excavating the grounds of a former home for unwed mothers which authorities say contains the remains of around 800 babies and young children who died there.
"It's a very, very difficult, harrowing story and situation," Irish Prime Minister Micheal Martin said Monday. "We have to wait to see what unfolds now as a result of the excavation."
The former Bon Secours Mother and Baby Home in western Ireland — which closed in 1961 and was run by Catholic nuns — was one of many mother-and-baby homes during the 20th century in the European country. The homes housed unmarried pregnant women as well as tens of thousands of orphans, according to The Associated Press.
Historian Catherine Corless tracked down death certificates in 2014 for nearly 800 children who died at the Bon Secours Mother and Baby Home between the 1920s and 1961. However, she could only find a burial record for one child, the AP reported.
A mass grave was later discovered by investigators in an underground sewage structure at the home. DNA analysis found the structure contained the remains of infants and young children between the ages of 35 weeks gestation and 3 years old, according to the AP.
Family members and survivors will soon have the opportunity to view the works, according to Daniel MacSweeney, who is leading the exhumation of the infant remains.
"This is a unique and incredibly complex excavation," MacSweeney said in a statement.
Any remains recovered from the site will be analyzed and preserved by forensic experts. Identified remains will be returned to family members, while unidentified remains will be buried. The work is expected to take two years to complete, the AP reported.
The sisters who ran the former Bon Secours Mother and Baby Home previously offered a "profound apology," acknowledging they failed to protect the dignity of the women and children that lived there, according to the AP.
In 2021, Prime Minister Martin issued a former state apology after a report found that 9,000 children died in 18 mother-and-baby homes during the 20th century in Ireland.
Daniel MacSweeney and Ireland's National Police and Security Service, An Garda Síochána, did not immediately respond to Fox News Digital's request for comment.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

3 hours ago

• Yahoo

Alcohol should have labels warning drinkers of cancer risks, charities say

Cans and bottles of beer, wine and spirits should explicitly warn drinkers that alcohol causes cancer, an unprecedented alliance of doctors, charities and public experts have said. Warning labels would tackle 'shockingly low' public awareness in the UK that alcohol is proven to cause seven forms of cancer and 17,000 cases a year of the disease, they claim. Dozens of medical and health organisations have written to Keir Starmer urging him to take the radical step of compelling alcohol producers to include such warnings in order to improve public health. The labels must be 'bold and unambiguous', said the World Cancer Research Fund (WCRF), which coordinated the letter. 'The evidence is clear: health labelling on alcoholic drinks is urgently needed in the UK to help save lives,' it said. 'They should carry strong, clear messages about the health risks, which include the risk of cancer, far beyond vague advice like 'consume in moderation'.' Kate Oldridge-Turner, the WCRF's head of policy and public affairs, said: 'Providing alcohol warning labels would empower millions to make informed choices by clearly understanding the risks.' Evidence cited by charities such as the WCRF and Cancer Research UK shows that alcohol increases the risk of breast, bowel, stomach, head, neck, liver and mouth cancer. Ireland is to become the first country in the world to include cancer warning labels on alcoholic products. From next May, alcohol sold in the republic will have to carry a warning that 'there is a direct link between alcohol and fatal cancers'. The labels will also warn that drinking can cause liver disease and affect foetuses. Prof Sir Ian Gilmore, the chair of the Alcohol Health Alliance, urged the UK to follow suit. He said: 'We must look to the fearless work of our neighbours in Ireland whose new labelling policy provides a level playing field for all producers, leaving no room for loopholes or hiding information behind QR codes or tiny print. 'Improved alcohol labelling, including clear health warnings about the link to cancer, is not just a public health measure, it's a fundamental consumer right. People deserve to know the risks so they can make informed choices about their health. But current labels and weak regulations are keeping drinkers in the dark.' The drinks industry dismissed the call and said warnings would make drinkers anxious. A spokesperson for the Portman Group, a drinks industry-funded body that oversees alcohol labelling in the UK, said: 'Whilst we do not dispute the link between alcohol and certain cancers, and that drinking at harmful levels is dangerous and increases risks, blanket cancer warning labels are not a proportionate policy measure and do not put the risks into an appropriate context. 'This can create unnecessary anxiety, eroding trust in health advice and alienating the very people who require support.' The spokesperson said most alcohol products already included advice from the chief medical officers of the UK's four home nations to drink no more than 14 units of alcohol a week. 'Most people already drink within this guidance, which means their risks for associated diseases are low', they said. In February, the World Health Organization's European office declared: 'Clear and prominent health warning labels on alcohol, which include a specific cancer warning, are a cornerstone of the right to health.' In a report, it urged governments to introduce them to help reduce alcohol-related harm and raise awareness of the link between drinking and cancer. Dr Gauden Galea, a WHO adviser, said in the report that policymakers should 'resist all the pressure that will inevitably come from commercial actors' who claim such warnings do not work. In January, Vivek Murthy, the US surgeon general under the then president, Joe Biden, said cancer warning labels were needed because drinking led to about 100,000 cancer diagnoses a year in the US. It was the third most common preventable cause of cancer after tobacco and obesity, he added. A Department of Health and Social Care spokesperson said: 'Drinking alcohol increases the risk of a range of health issues, including several cancers. That is why we recommend people drink within the UK chief medical officer's alcohol guidelines of fewer than 14 units a week, and strongly recommend these are displayed clearly on all alcohol products. 'We recognise the need for more action on the impact of alcohol on health; for too long there has been an unwillingness to lead on this issue. Our plan for change will shift healthcare towards prevention, including through early intervention, to support people to live longer, healthier lives across the UK.'

Yahoo

8 hours ago

• Yahoo

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and CHICAGO, June 20, 2025 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, highlighting improved glycemic outcomes for individuals with insulin-intensive type 2 diabetes on the MiniMed™ 780G* system under investigational use. Participants in a clinical trial achieved an average 8.6% increase in Time in Range (TIR), reaching 84.9%, well above the ADA goal of 70%, and a HbA1C reduction from 7.7% to 6.9%, meeting ADA targets for diabetes management. Separately, results from the Medtronic LENNY trial were publishedi in The Lancet Diabetes & Endocrinology. This multi-center, randomized controlled, crossover trial evaluated the MiniMed™ 780G system in young children (ages 2-6 years) with type 1 diabetes in a home setting. Results showed those using the MiniMed™ 780G system with SmartGuard™ achieved a 0.6% lower HbA1C and 9.9% higher Time in Range when compared to a baseline therapy of manual mode or hybrid closed loop without autocorrections. Parents and caregivers also reported improved sleep quality and lower fear of hypoglycemia when the system was used in auto mode (with SmartGuard™) compared to manual mode. Benefits of automated insulin delivery (AID) systems for type 2 diabetesWhile the standard of care for type 2 diabetes often includes lifestyle modifications and oral medications, many individuals require intensive insulin therapy to achieve optimal glucose management. The ADA's 2025 Standards of Careii now endorse the use of AID systems for adults with insulin-intensive type 2 diabetes, recognizing their potential to significantly improve clinical outcomes — an important validation of the growing role of diabetes technology in transforming chronic disease management. A 31-site single arm trial evaluated the MiniMed™ 780G system paired with the Simplera Sync™ sensor in a cohort of 236 individuals with type 2 diabetes. Results were promising across all clinical outcome metrics including Time in Range (TIR), Time in Tight Range (TITR), Time Above Range (TAR) compared to the run-in period where hybrid closed loop (auto basal only) or open-loop delivery was used. Time below range (TBR) remained stable. "As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin," said Dr. Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. "Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before."Baselinea Studyb Change (Study - Baseline) P Participants, N 236 232 -- -- Time in AHCL, % -- 92.4 ± 15.7 -- -- A1C, % 7.7 ± 0.9 6.9 ± 0.7c -0.8 ± 0.9c <0.0001 Mean SG, mg/dL 152.9 ± 21.2 140.7 ± 13.3 -12.3 ± 19.5 <0.0001 CV of SG, % 25.1 ± 4.8 25.6 ± 4.8 0.4 ± 3.3 0.073h TBR <54 mg/dL, % 0.0 ± 0.1 0.0 ± 0.1 -0.0 ± 0.1 0.277 TBR <70 mg/dL, % 0.3 ± 0.5 0.3 ± 0.4 0.0 ± 0.5 0.056 TITR 70-140 mg/dL, % 45.3 ± 19.7 58.1 ± 13.6 13.0 ± 18.8 <0.0001h TIR 70-180 mg/dL, % 76.4 ± 15.9 84.9 ± 9.7 8.6 ± 14.4 <0.0001 TAR >180 mg/dL, % 23.4 ± 15.9 14.8 ± 9.7 -8.6 ± 14.5 <0.0001 TAR >250 mg/dL, % 3.5 ± 5.2 1.7 ± 2.5 -1.8 ± 4.6 <0.0001 TDD, U 61.0 ± 36.1 76.1 ± 44.1 14.5 ± 25.1 <0.0001 Basal and bolus insulin Total basal, U 34.6 ± 21.3 39.8 ± 23.9 4.9 ± 16.8 <0.0001 Total bolus, U 26.5 ± 20.7 36.3 ± 23.8 9.6 ± 15.1 <0.0001 Auto bolus, U -- 13.7 ± 11.1 -- -- Auto bolus, %TDD -- 17.2 ± 8.5 -- -- Auto bolus, %Total bolus -- 39.3 ± 21.8d -- -- System-initiated insulin Automated insulin, U 0.5 ± 3.4 51.2 ± 33.4 50.7 ± 33.7 <0.0001 Automated insulin, %TDD 0.9 ± 5.8 65.9 ± 17.3 65.0 ± 17.8 <0.0001 Daily carbohydrate, g 119.1± 87.4 127.7 ± 88.9 7.7 ± 84.6 0.571 ICR 7.6 ± 4.0d 6.9 ± 3.8e -0.6 ± 1.5f <0.0001 Weight, kg 98.0 ± 22.8g 98.4 ± 23.0c 0.7 ± 4.7c 0.006 BMI, kg/m2 34.0 ± 7.3g 34.2 ± 7.4c 0.2 ± 1.7c 0.006 Table 1. Glycemic outcomes, insulin delivery and weight during MiniMed™ 780G system use with the Simplera Sync™ sensor in adults with type 2 diabetes Data are shown as mean± loop (with or without predictive low glucose management) or HCL. AHCL was inadvertently (temporarily) enabled on 13 represent the last 6 weeks of the study period with glucose target set at the investigator's dN=231, eN=228. fN= two-sided t-test; otherwise, Wilcoxon signed-rank Body mass index; CV, Coefficient of variation; ICR, Insulin-to-carb ratio; SG, Sensor glucose; TAR, Time above range; TBR, Time below range; TIR, Time in range; TITR, Time in tight range; TDD, Total daily dose; U, MiniMed™ 780G system has not been approved for use in type 2 diabetes by U.S. FDA or other regulatory bodies. Impact on families of young children with diabetesManaging type 1 diabetes in young children and toddlers can be challenging for families. Data from the Lenny trial, published in The Lancet Diabetes & Endocrinology, highlighted how young children aged 2-6 years old achieved improved glycemic outcomes using the MiniMed™ 780G system. "To preserve brain development and minimize long-term diabetes complications, it is essential that blood glucose concentrations are maintained close to healthy ranges from disease onset in early life," said Prof. Tadej Battelino, MD, Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Slovenia. "We are hopeful that if the data continues to be strong, the MiniMed™ 780G system can help make this possible." After a run-in phase, subjects using the MiniMed™ 780G system with the Guardian™ 4 sensor were randomized into two sequences, consisting of a 12-week auto mode period (advanced hybrid closed loop), a 2-week wash-out phase and 12-week manual mode period (with suspend before low feature activated), or vice-versa. In total, there were 98 subjects across 12 centers in 4 countries. Results showed significantly** better glycemic management in auto mode, as shown in Figure 1 and Table 2 below. With no severe hypoglycemic events, the study showed an acceptable safety profile. Participants in auto mode spent on average 145 minutes per day more in range than those in manual mode. This improvement was primarily driven by a reduction in hyperglycemia, which is a major contributor to long-term complications. "We're hopeful that if the data continues to be strong, we will receive future indication expansion so the most vulnerable group, small children under 7 years, and their families can also benefit from this technology ", said Prof. Ohad Cohen, M.D., senior global medical affairs director, Medtronic Diabetes. Table 2: Glycemic metrics during the run-in phase, the manual mode period, and the auto mode Manual Mode Auto Mode HbA1c, % 7.53 ± 0.96 7.61 ± 0.91 7.00 ± 0.53 HbA1c, mmol/mol 58.8 ± 10.5 59.7 ± 9.9 53.0 ± 5.8 Mean glucose, mg/dl 169.6 ± 25.7 169.1 ± 23.1 150.2 ± 10.7 SD of SG, mg/dl 65.0 ± 14.7 65.4 ± 13.2 61.8 ±10.9 GMI, % 7.4 ± 0.6 7.4 ± 0.5 6.9 ± 0.3 Table 2: Glycemic metrics during the run-in phase, the manual mode period, and the auto mode period. During manual mode, the suspend before low (SBL) feature was activated. During run-in, the system was also used in manual mode with SBL activated. Data are shown as mean ± SD. The emotional toll of diabetes for parents and caregiversManaging type 1 diabetes in toddlers and young children can be emotionally stressful for parents and caregivers due to the need for constant blood sugar monitoring, dietary management, insulin administration and disrupted routines and sleep. A survey of caregivers in the LENNY trial indicated that when their child used auto mode, they experienced relatively low fear of hypoglycemia and high sleep Manual Mode Auto Mode Parent hypoglycemia fear survey (HFS-P) 44.75 ± 14.9 42.9 ± 13.3 40.9 ± 13.2 Pittsburgh Sleep Quality Index (PSQI) 7.1 ± 3.8 7.1 ± 4.0 5.9 ± 3.2 Table 3: Parent hypoglycemia fear survey and Pittsburgh Sleep Quality Index during the run-in phase, the manual mode period and the auto mode period. During manual mode, the suspend before low (SBL) feature was activated. During run-in, the system was also used in manual mode with SBL activated. Medtronic will seek future expansion of indications for a broader populationThe MiniMed™ 780G system currently is not indicated for use in in type 2 diabetes or young children under 7 years old by the U.S. Food and Drug Administration (FDA) or other regulatory bodies. Medtronic intends to work with global regulators towards expanding access to its diabetes technology for insulin-intensive type 2 diabetes, as well as a lower age indication for those with type 1 diabetes. About the Diabetes Business at Medtronic Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. *MiniMed™ 780G system is for type 1 ages 7 years and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. See the User Guide for a detailed list of information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For details, see Significance was shown via confidence intervals§ Refers to SmartGuard™ feature. Individual results may vary.† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off. i Battelino et al. Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial; Lancet Diabetes Endocrinol 2025ii American Diabetes Association Professional Practice Committee: Diabetes Care 2025;48(Supplement_1):S146–S166 Contacts:Ashley Patterson Ryan Weispfenning Global Communications Investor Relations +1-818-576-3025 +1-763-505-4626 View original content to download multimedia: SOURCE Medtronic plc

Yahoo

18 hours ago

• Yahoo

Human Papillomavirus (HPV) Vaccines Strategic Business Research Report 2024-2025 & 2030 - Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake

The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis of market trends and growth drivers, providing vital insights for businesses. Key highlights include the evolution of vaccine formulations, such as nonavalent vaccines targeting multiple HPV strains, which are crucial in preventing HPV-related cancers globally. Strategic vaccination programs and improved distribution strategies are driving market expansion, particularly in emerging economies. Despite barriers like misinformation and hesitancy, increased public awareness and partnerships with organizations like Gavi are expected to enhance uptake, especially in high-burden regions. The report also assesses the impact of global tariff developments on the HPV vaccines market. Human Papillomavirus (HPV) Vaccines Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report" report has been added to global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Papillomavirus (HPV) Vaccines market. Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions. The Growth in the HPV Vaccines Market Is Driven by Several is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women's health and cancer prevention, along with WHO's cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines Are Vaccine Formulations and Distribution Strategies Evolving?HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global Is Uptake Increasing and What Barriers Remain?Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden Insights: Market Growth: Understand the significant growth trajectory of the Tetravalent segment, which is expected to reach US$5.8 Billion by 2030 with a CAGR of a 9.5%. The Nonavalent segment is also set to grow at 11.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 13.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Barinthus Biotherapeutics, Bharat Biotech, BioNTech SE, CanSino Biologics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 279 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.5 Billion Forecasted Market Value (USD) by 2030 $9.7 Billion Compound Annual Growth Rate 9.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability FOCUS ON SELECT PLAYERS Barinthus Biotherapeutics Bharat Biotech BioNTech SE CanSino Biologics Inc. GlaxoSmithKline plc Inovio Pharmaceuticals Johnson & Johnson Merck & Co., Inc. Moderna, Inc. Novavax, Inc. Pfizer Inc. Sanofi S.A. Serum Institute of India Sinovac Biotech Ltd. Takeda Pharmaceutical Company Valneva SE Vaxart, Inc. Walvax Biotechnology Co., Ltd. Wantai BioPharm Xiamen Innovax Biotech Co., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papillomavirus (HPV) Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio